Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells

RUTH THOMPSON1,3, MARK MEUTH1, PENELLA WOLL2, YONG ZHU1 and SARAH DANSON2

1Institute for Cancer Studies, Sheffield University Medical School, Beech Hill Road, Sheffield S10 2RX; 2Academic unit of Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK

Received June 30, 2011; Accepted August 8, 2011

DOI: 10.3892/ijo.2011.1187

Abstract. Acquired chemoresistance is a major obstacle in successful treatment of small cell lung cancer (SCLC). DNA damage responses can potentially contribute to resistance by halting the cell cycle following exposure to therapeutic agents, thereby facilitating repair of drug-induced lesions and protecting tumour cells from death. The Chk1 protein kinase is a key regulator in this response. We analysed the status of cell cycle checkpoint proteins and the effects of the Chk1 inhibitor Gö6976 on cisplatin toxicity in SCLC cell lines. IC50s for cisplatin were determined using the MTT assay in six SCLC cell lines. Effects on cell cycle distribution and apoptosis were determined by flow cytometry and caspase 3 activation in the presence or absence of the Chk1 inhibitor Gö6976. The activation of checkpoint proteins was determined by Western blotting. Cell lines were divided into chemosensitive and chemoresistant groups on the basis of our results. While checkpoint responses were detected in these cell lines through Western blotting, some of these responses were delayed or weaker than those seen in other cell types in response to DNA damage and replication stress. Gö6976 significantly (p<0.05) enhanced the levels of apoptosis seen in response to a clinically relevant dose of cisplatin (<6 µM) and decreased drug-induced G2 arrest in chemosensitive cells. Our data suggest a role for Chk1 in chemoresistance of SCLC cells and a potential approach to improve initial response of SCLC to cisplatin therapy.

Introduction

Lung cancer is the leading cause of cancer-related death in the developed world in both sexes (1). Small cell lung cancer (SCLC) accounts for ~20% of lung cancers. SCLC is distinguished from NSCLC (non-small cell lung cancer) by characteristic biological and pathological features and by its initial chemosensitivity. Standard first line treatment of SCLC with platinum-based chemotherapy results in objective tumour responses in ~80% of patients and symptomatic benefit in even more. Unfortunately, most patients soon relapse with chemoresistant disease and ultimately die of the disease (2). Treatment of relapsed or refractory SCLC is an ongoing problem for oncologists and patients and new approaches to overcome platinum chemoresistance are urgently required.

Cisplatin is widely used in the treatment of solid tumours. Its cytotoxic activity is based on its interaction with cellular DNA leading to the formation of adducts derived from intra- or interstrand crosslinks (ICLs) (3). Such crosslinks result in delayed S phase transit and ultimately G2 arrest (4,5). It has been proposed that cisplatin-induced interstrand crosslinks are processed to double-strand breaks (DSBs) following an encounter with a replication fork (6). Radiation-induced DSBs induce ATM (Ataxia telangiectasia mutated) autophosphorylation which in turn leads to cell cycle arrest via activation of p53, Chk2 and, ultimately, Chk1. It has been shown that ATM is also induced in response to cisplatin treatment (7) but interestingly, this ATM phosphorylation is attenuated in nucleotide excision repair (NER) deficient cells (8). This suggests that the ICLs are initially recognised by the NER system which processes them to lesions that lead to DSBs, ATM-mediated cell cycle arrest, and DSB repair. This response may contribute to chemoresistance by enhancing repair of cisplatin-induced lesions in cancer cells.

Abrogating checkpoint pathways that trigger cell cycle arrest can induce apoptosis in cisplatin-resistant cells (9). 7-hydroxyxystaurorosporine (UCN-01), a protein kinase antagonist, preferentially inhibits protein kinase C but also inhibits the serine/threonine kinase AKT, cyclin-dependent kinases (CDKs) and checkpoint kinase 1 (Chk1) (10,11). UCN-01 has been shown to potentiate the toxicity of cisplatin by abrogation of G2 and S phase arrest (12,13). In NSCLC cell lines, UCN-01 dramatically reduced the proportion of cells in cisplatin-induced G2 arrest and increased the ability of cisplatin to induce apoptosis. This effect was only seen when the inhibitor was added 16 h after the cisplatin treatment and not when UCN-01 was added before cisplatin. This was thought to be because UCN-01 itself causes G1 arrest (14).

Despite the initial promise of UCN-01 in vitro, phase I clinical trials revealed a strong affinity to the human plasma protein α1-acid glycoprotein resulting in a prolonged half-life...
and decreased bioavailability (15). Furthermore, UCN-01 acts as an inhibitor of many kinases that could result in adverse side-effects in patients. As a potential alternative, Gö6976 is an indolocarbazole which is similar in structure to UCN-01 but has lower toxicity and greater selectivity for inhibiting protein kinases than UCN-01 and is unaffected by the presence of human serum. Importantly it also abrogates S and G2 arrest via inhibition of the checkpoint kinase protein Chk1 (16).

While cellular responses to cisplatin have been widely studied in many types of cultured tumour cells, little is known of the response to SCLC cells to this agent despite its use as a first-line agent in therapies for these tumours, largely because of the difficulties in growing SCLC cells in vitro. The large floating aggregates these non-adherent cells form in culture hinder many in vitro techniques. The aim of this study was to characterize checkpoint responses in cultured SCLC cells and to determine whether these responses could be exploited to improve response to this agent. Here we show that there is a marked difference in the cell cycle response to cisplatin between the sensitive and resistant SCLC cell lines tested here and that inhibition of the DNA damage response protein Chk1 led to enhancement of cell death at clinically relevant doses of cisplatin, most notably in the primary, sensitive SCLC cell lines.

Materials and methods

Cell cultures. SCLC cell lines H69, H82, H345 and H711 were acquired from ATCC. The Lu165 cell line was a gift from Dr T. Terasaki (National Cancer Center, Tokyo Japan). The Glc19 cell line was a gift from The Groningen Lung Cancer Group (Groningen, The Netherlands). The cells were maintained in suspension cultures in RPMI medium supplemented with 10% foetal calf serum (FCS). Cells were incubated at 37°C, 5% CO₂. Cisplatin (Sigma-Aldrich, Dorset, UK) was dissolved in water and Gö6976 (Sigma-Aldrich) was dissolved in DMSO (Sigma-Aldrich). Both were stored in the dark at -20°C. Cells were incubated for 1 h with Gö6976 prior to 48 h cisplatin treatment.

MTT assay. Cells were plated in 24-well plates (1 ml suspension/well) in RPMI (+10% FCS) at a concentration of 5x10⁴ cells/ml and incubated for 4 h at 37°C prior to treatment (17). The cells were treated with cisplatin, each dose was plated in triplicate. Followed by the addition of 100 µl/well thiazolyl blue tetrazolium bromide (MTT) solution (5 mg/ml; Sigma-Aldrich) the plates were incubated at 37°C for ~30 min or until sufficient purple coloration developed. The contents of each well were transferred to a 1-ml Eppendorf tube and centrifuged at 2000 x g for 5 min. The supernatants were removed and cell pellets left in the tube. The cells were resuspended in 100 µl DMSO by pipetting until all crystals had dissolved. The contents of each Eppendorf were transferred to one well of a 96-well plate which was read in a plate reader at a wavelength of 570 nm (ref. 690 nm). The optical density of the untreated controls was taken as 100% cell viability and all subsequent readings were calculated as a percentage of the control.

Caspase 3 activation assay. To quantify levels of apoptosis, the active caspase 3 levels were ascertained using a Caspase 3 detection kit (Axxora, Nottingham, UK) (18). The cells were processed further to allow simultaneous analysis of the cell cycle by flow cytometry. Cells (5x10⁴/ml) were plated in 6-well plates (3 ml suspension/well) and treated with the stated dose of cisplatin for 48 h. Following treatment, cells were incubated with the caspase-3 inhibitor DEVD-FMK conjugated to FITC (1 µl/ml) then resuspended in phosphate-buffered saline (PBS) containing 50 µg/ml propidium iodide (PI), 100 µg/ml RNase A and 0.1% Triton X-100 and incubated at -4°C in the dark for 60 min. Analysis was carried out on a Beckton-Dickinson FACSCalibur cytometer using CellQuest Pro software.

Cell cycle analysis. Cell cycle analysis was performed using flow cytometric evaluation of DNA content. Following cisplatin treatment, cell suspensions were washed once in PBS, and resuspended in ice cold 70% ethanol. Cells were stored at -20°C for at least 24 h to allow for perforation of the cell membrane. After fixing, the cells were washed in PBS, 5 µl RNase A was added to remove any RNA to which the PI could bind. PI solution (500 µl of 5 mg/ml) was added to dilute the RNase A to a final concentration of 100 µg/ml. The cells were stored in the dark at -4°C overnight before FACs analysis.

Western blotting. Cell lysates were prepared and fractionated on SDS-PAGE gels before being blotted onto nitrocellulose (Whatman, Schleicher and Schull, Dassel, Germany) as described previously (19). Protein bands were visualized using the ECL detection system (GE Healthcare, Little Chalfont, Buckinghamshire, UK) using antibodies recognizing ATM (GeneTex, Irvine, CA, USA), phospho-ATM (Ser 1981) (Epitomics, Burlingame, CA, USA), total Chk1, phospho-Chk1 (Ser 296), phospho-Chk1 (Ser 345), phospho-H2AX (Cell Signaling, Herts, UK), β-actin (Sigma-Aldrich) and RPA34 (Calbiochem, Nottingham, UK).

Results

Chemosensitivity of SCLC cell lines to cisplatin. Platinum drugs are the primary chemotherapeutic agents used to treat SCLC. The cisplatin levels required to induce 50% cell death (IC₅₀) after 48 h treatment were determined for each cell line using the MTT assay. Dose-response curves were constructed for each cell line and the resulting IC₅₀ was calculated (Fig. 1A and B). The two out of the six cell lines derived from primary tumours prior to treatment (H69 and H82), and the cell line derived from a secondary tumour pretreated with drugs besides cisplatin (Glc19) were all relatively sensitive to cisplatin with IC₅₀ of 4-12 µM. In contrast, the three cell lines derived from secondary metastases of tumours pretreated with cisplatin (H345, H711 and Lu165) were considerably more chemoresistant than IC₅₀ of 40-100 µM (Fig. 1B).

To assess whether decreased cell viability corresponded to increased levels of apoptosis, the levels of cleaved caspase 3 were measured. Caspase 3 cleavage is a marker of cells undergoing apoptosis. Fig. 1C shows that levels of cleaved caspase 3 corresponded to the loss of viability determined by the MTT assays in the sensitive cells. The data are insufficient to make the same conclusion for the resistant cells but there was a small but significant (p=0.0103, paired t-test) increase in the level of caspase 3 activation in the resistant cells up to the cisplatin concentration of 25 µM (Fig. 1C).
Cell cycle response to cisplatin. To determine the effect of cisplatin on cell cycle distribution of the SCLC cell lines, the cell cycle profiles were visualised using fluorescence-activated cell sorting (FACS) following treatment with the clinically achievable doses of 1 and 6 µM cisplatin for 48 h. There was a marked difference in the cell cycle response of the two groups. The three cisplatin-sensitive cell lines exhibited accumulation in G2 whereas the three more chemoresistant cell lines demonstrated S phase arrest. One cell line from each group is shown (Fig. 2A). Statistical analysis of data from five independent experiments showed that the changes in cell cycle profiles were significant (p<0.01, Two-Way ANOVA). All cell lines also showed a visible increase in cells having a subG1 DNA content following cisplatin treatment (Fig. 2B). Treatment with the mitotic inhibitor nocodazole revealed that the H345 cells did not pass through G2/M before arresting in S while the H82 cells arrested in G2 prior to mitosis (data not shown).

Activation of checkpoint proteins in SCLC cells in response to cisplatin. To determine whether the differences in cell cycle response to clinically achievable doses of cisplatin were the result of defects in the DNA damage checkpoints, Western blot analysis was performed to determine the presence of important checkpoint proteins and the phosphorylation of these proteins following cisplatin treatment. This analysis revealed that Chk1 was weakly phosphorylated in response to drug treatment at both the ATM/ATR-mediated phosphorylation site (Ser 345) and the autophosphorylation site (Ser 296) (20) in response to the clinically achievable dose of 5 µM cisplatin. ATM phosphorylation also occurred in both subsets of cells. Interestingly, RPA hyperphosphorylation [that in some reports is associated with cells committed to death (21)] was only seen in the sensitive cells following cisplatin treatment. Western blot analysis of the phosphorylated forms of these proteins in cell extracts prepared from cells treated for 1, 2 or 24 h were performed with one sensitive and one resistant cell line to analyse the rapidity of these phosphorylation events. Analysis of Chk1 phosphorylation in H82 and H345 cells at these earlier times post treatment revealed that Chk1 phosphorylation was not detectable until 24 h following treatment in either cell line. Phosphorylation of ATM and H2AX was only detected in the resistant H345 cell line after 24 h and this response was weaker than in the sensitive H82 cell line (Fig. 2D). Thus, while checkpoint responses can be detected in SCLC cells, some of these responses are delayed or weaker than those seen in other cell types in response to DNA damage and replication fork stress (22).

Effects of Gö6976 on apoptosis and cell cycle distribution in SCLC cell lines following cisplatin treatment. Recent work by several groups has shown that Chk1 plays a key role in protecting S phase arrested cells from apoptosis following treatment with replication inhibitors (reviewed in ref. 23). To determine whether the response of the SCLC cells to cisplatin could be enhanced by inhibiting Chk1, cells were pre-incubated for 1 h with DMSO or 100 nM of the Chk1 inhibitor Gö6976 prior to 48 h cisplatin treatment. MTT assays and Western blotting were used to determine the ideal Gö6976 concentration.
to inhibit Chk1 but not induce high levels of death in both sensitive and resistant cells (data not shown). To determine the efficacy of Gö6976 in inhibiting Chk1, Western blotting for the Chk1 autophosphorylation site Ser 296 were carried out following treatment with cisplatin, Gö6976 and combination treatment. This revealed that Gö6976 inhibited cisplatin-induced Chk1 autophosphorylation (one cell line from each group is presented in Fig. 3A). MTT analysis revealed that Gö6976 only decreased the cisplatin IC50 in the sensitive cells (Fig. 3B). To analyse whether Gö6976 increased levels of death at clinically relevant doses of cisplatin, a more relevant measure with regards to treatment, the percentage of cells with subG1 DNA content was analysed. SubG1 is indicative of cell debris which indicates cell death. The subG1 proportion of cells was significantly increased following combination treatment compared to treatment with cisplatin alone (Glc19 p=0.01, H69 p=0.0035, H82 p=0.001, paired t-test) (Fig. 3C). Among the resistant cell lines, H345 showed a significant increase in the fraction of cells with subG1 DNA content after combination treatment (p=0.019, paired t-test). While the Lu165 cells also showed some increase,
it did not reach significance. The H711 cells showed little or no effect. Similar results were obtained when cleaved caspase 3 was measured as an indicator of apoptosis (data not shown).

Gö6976 has been reported to enhance the cytotoxicity of DNA damaging agents by abrogating cell cycle arrest. To test this hypothesis, cell cycle profiles of cells treated with cisplatin alone and cisplatin with Gö6976 were examined. Cell cycle profiles of cells treated with 1 µM cisplatin are shown here as at 6 µM the higher levels of subG1 population in the H82 cells make the profiles difficult to compare. In the chemosensitive H82 cells, there was a 60% reduction in the proportion of G2 cells following combination treatment (p<0.001, Two-Way ANOVA) and there was a corresponding increase in the level of cells with subG1 DNA content (p<0.001, Two-Way ANOVA). In some cases there was a reduction in the percentage of the resistant H345 cells in S phase following combination treatment but this was not consistent and did not reach significance although there was a significant increase in the level of cells with a subG1 DNA content (Fig. 4).

Effects of the drug combination on apoptosis and cell cycle distribution were not altered by the order of administration. Previous work has indicated the necessity for UCN-01 to follow cisplatin treatment in order to potentiate toxicity (14). In
Thompson et al: Enhancing cisplatin cytotoxicity in SCLC cells

In contrast, Gö6976 has been administered 1 h prior to cisplatin treatment (24) or 24 h following cisplatin treatment (16). To determine whether the sequence of Gö6976 administration affected cisplatin-induced apoptosis and cell cycle arrest, the agent was added either 1 h before or 24 h after cisplatin treatment of sensitive or resistant SCLC cells. There was no significant difference in cell cycle distribution or the level of cells with subG1 DNA content in either chemosensitive or chemoresistant cells (Fig. 5A and B).

Effect of cisplatin and Gö6976 on RPA34 hyper-phosphorylation and γH2AX formation in SCLC cell lines. Replication protein A (RPA) binds to single-strand DNA (ssDNA) formed during the disruption of DNA replication and is involved in DNA replication, repair and recombination. Once bound to single-strand DNA, it recruits the ATRIP/ATR complex which acts to initiate the cell cycle arrest checkpoint (25). Previous work in our group has shown a dramatic increase in RPA 34 hyper-phosphorylation in Chk1-depleted cells treated with replication inhibitors followed by enhanced levels of γH2AX (21,26). To assess the RPA hyper-phosphorylation and γH2AX levels in the chemosensitive and chemoresistant cell lines used here, protein was extracted from cells 48 h after treatment with 5 µM cisplatin, 100 nM Gö6976, or both in combination (with Gö6976 added 1 h before cisplatin). The RPA and γH2AX levels were analysed by Western blot analysis (Fig. 6). Hyper-phosphorylation slows the mobility of RPA on a polyacrylamide gel resulting in a band-shift of the hyper-phosphorylated protein. Sensitive H82 cells showed RPA hyperphosphorylation following treatment with cisplatin alone which was enhanced by Gö6976 combination. Cells treated with Gö6976 alone showed γH2AX and this was further enhanced by combination treatment with cisplatin. The resistant cells showed a much weaker response for both γH2AX and RPA.

Discussion

The treatment of SCLC presents major challenges. Strategies to overcome drug resistance are needed to improve on current results obtained in clinical practice. The six cell lines studied were characterised into two groups based on their sensitivity to the cancer chemotherapy agent cisplatin. The mean peak plasma concentration attained in clinical use of cisplatin is 2 µg/ml which is equivalent to 6.66 µM (27). The chemosensitive group exhibited decreased cell viability and increased levels of the apoptosis executioner protein, caspase 3 following 48 h of treatment with relatively low doses of cisplatin (IC50 4-12 µM). The chemoresistant group required much higher...
cisplatin doses (IC₅₀ 40-100 µM) to achieve the same levels of cell death after 48 h treatment.

The chemosensitivity to cisplatin of the SCLC cell lines was determined using MTT and caspase 3 activation assays. These results corresponded well, with around 50% of cells expressing the cleaved form of caspase 3 at the IC₅₀ dose determined by the MTT assay indicating that the reduction in cell number demonstrated in the MTT assay was due to apoptosis.

The differential cell cycle arrest between the two groups was interesting especially as previous studies in other human cancer cells suggest that cisplatin induces delayed S phase transit and ultimately G2 arrest (4,27). S phase arrest as seen in the chemoresistant cells in this study has only been documented in hamster cells and human cell lines modified to overexpress various repair proteins (13,28). There is less γH2AX and RPA hyperphosphorylation in the resistant H345 cells following treatment than in the sensitive H82 cells. This could be indicative of low levels of cisplatin uptake into the cells or high incidence of drug efflux. However, the fact that cisplatin induces a marked S phase arrest in the resistant cells indicates that the drug is entering the cell and causing damage therefore it is more likely that the mechanism of resistance is due to rapid repair of cisplatin-induced lesions in the resistant cells. We therefore speculate that the aberrant S phase arrest in resistant cells may contribute to cisplatin resistance. Chk1 phosphorylation was weak and delayed relative to responses previously demonstrated by many groups in other cancer cell lines in response to damaging agents (22,29). The presence of hyper-phosphorylated RPA in sensitive cells indicates evidence of persistent ssDNA after cisplatin treatment. This is further enhanced by combination treatment with Gö6976.

Previous work has demonstrated that the PKC/Chk1 inhibitor UCN-01 enhances cisplatin toxicity and abrogates cisplatin-
induced S phase (13) and G2 arrest (30) in various cells, both tumour and non-tumour. This has been demonstrated in NSCLC cell lines but not in SCLC cells (14). Unfortunately the use of UCN-01 in patients is not possible as it has a much increased half-life in human serum due to an unfavourable association with human α-acid glycoprotein (15). It also interferes with non-checkpoint kinases thus disrupting other pathways (31). Although Gö6976 is similar to UCN-01 in structure, it is less toxic (having a 20-fold higher IC_{50} in MDA-MB-231 cells than UCN-01) and does not interact with human α-acid glycoprotein (16). Like UCN-01, Gö6976 was originally identified as a PKC inhibitor and inhibits the Ca^{2+}-dependent α and β subtypes of PKC (32) but both UCN-01 and Gö6976 are extremely effective at abrogating DNA damage-induced S and G2 arrest (12,13,33,34). Following analysis of checkpoint proteins it has been concluded that this is due to the inhibition of Chk1 function (11,16,35). It is however important to note that Gö6976 is not specific to PKC and Chk1. It has also been shown to block neotrophin-induced signalling and autophosphorylation of the specific tyrosine kinase receptors TrkA and TrkB (36). It has also been reported that Gö6976 is a direct inhibitor of both the Janus-activated kinase JAK2 and the FMS-like tyrosine kinase 3 (FLT3) (37). It should be noted, however, that the involvement of these signalling pathways in the response to replication stress has not been documented. In addition to the known direct targets, Gö6976 will also affect proteins downstream of those mentioned above.

The cell cycle-dependent potentiation of cisplatin by UCN-01 in NSCLC cell lines was only seen when UCN-01 was added 16 h after cisplatin (14). This was proposed to be due to G1 arrest induced by UCN-01 when used alone. Gö6976 has no obvious effects on the cell cycle profiles of SCLC cell lines used here (except on the proportion of SubG1 cells) and experiments comparing the addition of Gö6976 before and after cisplatin indicate that the order of administration makes no difference to the effects (Fig. 5).

Here, Gö6976 abrogated cisplatin-induced cell cycle arrest in chemosensitive SCLC cells and potentiated cisplatin-induced apoptosis in both chemosensitive and chemoresistant cell lines at cisplatin levels relevant to clinical practice. This is demonstrated by data obtained from both SubG1 and caspase 3 activation analysis. The effect of Gö6976 is greater in the sensitive cells. This could be clinically valuable as further enhancing apoptosis in the primary tumours could reduce the risk of relapse or delay it by reducing the level of surviving cells. All the SCLC cell lines used here are p53 deficient. It has been suggested that in the absence of Chk1, p53-deficient tumour cells may die via a caspase 2-mediated pathway following exposure to ionizing radiation (38) although replication inhibitors trigger a caspase 3-dependent pathway (39). Western blot analysis failed to reveal activation of caspase 2 in these cells in the presence or absence of Gö6976 following cisplatin treatment in the SCLC lines tested (data not presented).

The cisplatin-induced G2 peak seen in the chemosensitive cells was significantly diminished following treatment with the Chk1 inhibitor, consistent with the previously established role of Chk1 in the G2 arrest (40). The cisplatin-induced S phase arrest in chemoresistant cells was affected to a lesser extent suggesting that another pathway is involved in the maintenance of S phase arrest. The discovery of a class of human interstrand crosslink-hypersensitive mutants carrying mutations in one of the Fanconi anaemia genes (41) led to speculation that there is an ATR-dependent but Chk1-independent pathway that works in tandem with the ATR-Chk1 pathway in maintaining the S phase checkpoint in response to interstrand crosslinks (42). Experiments involving single and combination treatments with Chk1 and FANCD2 siRNA revealed that cells with interference of one or the other showed a partial decrease in number of cells in S phase but cells with concomitant interference of both proteins exhibited a complete loss of S phase checkpoint activation (42). This could explain why Gö6976 has been reported to abrogate S phase arrest induced by other DNA-damaging drugs but does not abrogate cisplatin-induced S phase arrest here.

This study shows that Gö6976 decreased the cisplatin IC_{50} for sensitive cells and enhanced cisplatin cytotoxicity in several SCLC cell lines at the clinically achievable dose of 6 µM cisplatin. This suggests that Chk1 inhibitors could be used to enhance the cytotoxic effects of cisplatin in primary sensitive SCLC tumours but more work is required to elucidate the mechanisms of chemoresistance. Notably three new Chk1 inhibitors are in clinical development (43) and the higher specificity of these inhibitors could further improve this response. Future work should focus on investigating inhibitors such as these in SCLC in combination with standard treatment of cisplatin with etoposide.

Acknowledgements

The authors thank Susan Newton for her assistance with the flow cytometry and Anil Ganesh for his expert technical assistance. This work was funded by Yorkshire Cancer Research (MM) and Weston Park Cancer Appeal (RHT, SD, YMZ and PW). The funding bodies had no role in the study design, or in the collection, analysis or interpretation of data, neither any role in the preparation of the manuscript or its submission for publication.

References


